VKTX
Viking Therapeutics, Inc.
There isn't enough reported data to score VKTX yet.
VKTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VKTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
VKTX PE Valuation
VKTX has no meaningful PE right now: it lost money over the past year.
VKTX Forward outlook
There aren't enough analyst estimates for VKTX to show an outlook.
VKTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.41 | -$3.28 |
| Q2 2026 | -$4.67 | -$3.13 |
| Q1 2026 | -$4.15 | -$2.99 |
| Q4 2025 | -$3.19 | -$2.18 |
| Q3 2025 | -$2.13 | -$1.21 |
| Q2 2025 | -$1.54 | -$0.61 |
| Q1 2025 | -$1.16 | -$0.24 |
| Q4 2024 | -$1.01 | -$0.10 |
VKTX lost $5.41 per share over the past year, and its loss has widened in each of the last eight quarters.
VKTX Quarterly Revenue
VKTX's revenue is shrinking: $0 last quarter.
VKTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$138.2M | -$44.2M |
| Q2 2026 | -$125.2M | -$78.1M |
| Q1 2026 | -$114M | -$61.6M |
| Q4 2025 | -$85.3M | -$54.1M |
| Q3 2025 | -$94M | -$72M |
| Q2 2025 | -$47.1M | -$18.5M |
| Q1 2025 | -$52.3M | -$46.2M |
| Q4 2024 | -$31.2M | -$13.5M |
VKTX has burned cash in almost every quarter: −$463M over the past year, against −$225M the year before.
VKTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +1.8M shares |
| 1 year | +5.1% | +5.7M shares |
| 3 years | +18% | +18.2M shares |
| 5 years | +51% | +40M shares |
| Available history | +64% | +46.1M shares |
VKTX has 118M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $1.7M |
| Q1 2022 | $5.1M |
VKTX Net Leverage
VKTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VKTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.7 | Neutral |
| Stochastic | 17.7 | Oversold |
VKTX's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
VKTX PE vs Healthcare Sector
VKTX has no meaningful PE right now: it lost money over the past year.
VKTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.2 | 2.1% below |
| 20 week MA | $31.7 | 13% below |
| 50 week MA | $32.4 | 15% below |
| 100 week MA | $31.7 | 13% below |
| 200 week MA | $33.9 | 19% below |
VKTX is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VKTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.33 | $6.20 | -26% |
| 2021 | $6.20 | $5.18 | -16% |
| 2022 | $5.18 | $8.45 | +63% |
| 2023 | $8.45 | $18.6 | +120% |
| 2024 | $18.6 | $41.2 | +121% |
| 2025 | $41.2 | $37.2 | -9.7% |
| 2026 YTD | $37.2 | $27.6 | -26% |
VKTX has finished lower in three of the last six years. It's down 26% so far in 2026.